Amwell expects Q4 2026 revenue of $48M-$50M and adjusted EBITDA from breakeven to $1M (NYSE:AMWL)

Amwell (AMWL) expects Q4 2026 revenue of $48M-$50M and adjusted EBITDA from breakeven to $1M. CEO Ido Schoenberg highlighted progress toward profitability, aiming for positive cash flow and adjusted EBITDA for the year.

Original reporting
Published Nov 4, 2026, 2:46 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 2:55 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$AMWL
Bullish
medium confidence
Mentioned
$AMWL
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$AMWLBullishMed
01

Why it matters

The key tradable input is the explicit Q4 2026 revenue range and adjusted EBITDA trajectory, which can drive expectation changes for future quarters and risk premium.

02

Market read

Forward guidance with specific revenue and adjusted EBITDA ranges can move AMWL’s valuation by updating the market’s profitability and growth expectations.

03

What to watch

Without details on cash burn, payer mix, utilization trends, or backlog, the guidance’s durability and path to sustained profitability remain uncertain.

Relevance 7/10Novelty 6/10Timing: guidance referenced for Q4 2026, following the Q3 2026 earnings call context

Background

The article is an AI-generated earnings-call insights summary referencing AMWL’s execution toward profitability.

Company-level read

Ticker impact

$AMWLBullishMedium confidence
Context

American Well (AMWL) management is guiding Q4 2026 revenue to $48M-$50M and adjusted EBITDA from breakeven to $1M.

Expected impact

Likely upward bias if the market views the Q4 2026 revenue and EBITDA trajectory as credible versus expectations, otherwise downside if seen as conservative.

Evidence & confidence

The headline contains explicit forward guidance numbers, which are typically market-moving for a loss-making healthcare services/software name; however, the provided body excerpt does not include consensus comparisons or additional context to gauge surprise magnitude.

Market effects

Reinforces the market’s focus on profitability milestones and cash-flow progress for telehealth/healthcare services providers.

No clear regional spillover indicated by the provided text.

Limited, as the disclosure is company-specific and US-listed.

Counterpoint

If investors interpret the guidance as achievable only with aggressive cost control or delayed demand recovery, the stock could still face skepticism despite EBITDA improvement.

Key entities

  • American Well Corporation

    AMWL, telehealth/healthcare services provider issuing forward guidance for Q4 2026 revenue and adjusted EBITDA.

Related articles

$AMWLMed

American Well Corp (AMWL) Q3 2026 Earnings Call Highlights: Revenue Beat, Raised Guidance

American Well Corp (AMWL) reported Q3 2026 revenue of $49M, down 12.9% YoY. Subscription revenue fell 22.5% due to churn. Platform visits dropped 30.5% YoY. The VA letter of intent is non-binding, and the DHA contract conversion is pending. CEO Dr. Ido Schoenberg expressed optimism about negotiations and potential growth opportunities. The company expects Q4 adjusted EBITDA breakeven and raised guidance.

$AMWLMedAI 8/10

What American Well (AMWL) Said on Its Q3 Earnings Call

Amwell (AMWL) reported Q3 earnings with virtual primary care visits up 41% YoY, but total platform visits down 30.5%. Gross profit was $26M with a 53% margin. Q4 revenue is forecasted at $48M-$50M, with adjusted EBITDA expected to break even or turn positive. The company raised its full-year 2026 outlook, now expecting revenue of $204M-$206M and a reduced adjusted EBITDA loss. Amwell also discussed potential government contracts, including a nonbinding letter of intent from the VA.

$AMWLHigh

American Well Corp (AMWL): AMWELL® ANNOUNCES RESULTS FOR THE third QUARTER 2026

American Well Corp (AMWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMWELL® ANNOUNCES RESULTS FOR THE third QUARTER 2026 BOSTON, November 3 , 2026 –Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the third quarter ended September 30,

$AMWLMedAI 8/10

American Well (AMWL) Q2 2026 Earnings Call Transcript

American Well (AMWL) reported Q2 2026 revenue of $52 million, down 26.6% year over year, with subscription revenue of $25.7 million and AMG revenue of $24.4 million. Adjusted EBITDA loss was $1.15 million and net loss was $9.6 million. Full-year guidance was narrowed to $200-$205 million revenue and improved adjusted EBITDA loss to $9-$7 million. The Defense Health Agency issued an intent to award a sole-source contract.

$AMWLMed

American Well Corp (AMWL): AMWELL® ANNOUNCES RESULTS FOR THE Second QUARTER 2026

American Well Corp (AMWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMWELL® ANNOUNCES RESULTS FOR THE Second QUARTER 2026 BOSTON, August 4 , 2026 –Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the second quarter ended June 30, 2026